Similar articles

• Response to the letter to the editor entitled "diclofenac: increase of myocardial infarctions at low doses?" (PDS 13-0441) authored by K Brune.

  Varas-Lorenzo C, Castellsague J, Perez-Gutthann S. Varas-Lorenzo C, et al. Pharmacoepidemiol Drug Saf. 2014 Mar;23(3):329-30. doi: 10.1002/pds.3563. Pharmacoepidemiol Drug Saf. 2014. PMID: 24596324 No abstract available.
• Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.

  Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. Hernández-Díaz S, et al. Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):266-74. doi: 10.1111/j.1742-7843.2006.pto_302.x. Basic Clin Pharmacol Toxicol. 2006. PMID: 16611201
• Letter by Naimer regarding article, "Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study".

  Naimer S. Naimer S. Circulation. 2011 Nov 22;124(21):e552; author reply e555. doi: 10.1161/CIRCULATIONAHA.111.051607. Circulation. 2011. PMID: 22105203 No abstract available.
• Letter by Altman and Gonzalez regarding article, "Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study".

  Altman R, Gonzalez CD. Altman R, et al. Circulation. 2011 Nov 22;124(21):e554; author reply e555. doi: 10.1161/CIRCULATIONAHA.111.051128. Circulation. 2011. PMID: 22105205 No abstract available.
• [Cardiovascular side effects of non-steroidal anti-inflammatory drugs in the light of recent recommendations. Diclofenac is not more dangerous].

  Horváth VJ, Tabák GÁ, Szabó G, Putz Z, Koós CG, Lakatos P. Horváth VJ, et al. Orv Hetil. 2015 Mar 29;156(13):516-20. doi: 10.1556/OH.2015.30120. Orv Hetil. 2015. PMID: 25796279 Review. Hungarian.